Protein-protein interactions as druggable targets: Recent technological advances

Current Opinion in Pharmacology

Volumn 13, Issue 5, 2013, Pages 791-796

  Higueruelo, Alicia P ^a   Jubb, Harry ^a   Blundell, Tom L ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; PEPTIDOMIMETIC AGENT;

ALLOSTERISM; ARTICLE; DRUG BINDING SITE; DRUG DEVELOPMENT; DRUG SCREENING; DRUG TARGETING; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECONDARY STRUCTURE; PROTEIN STABILITY; SURFACE PLASMON RESONANCE;

DRUG DISCOVERY; PEPTIDES; PROTEIN BINDING; PROTEIN INTERACTION MAPS; PROTEINS;

EID: 84893018543     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2013.05.009     Document Type: Review

References (66)

1. Hopkins AL, Groom CR: The druggable genome. Nat Rev Drug Discov 2002, 1: 727-730. (Pubitemid 37361545)
2. Cochran AG: Antagonists of protein-protein interactions. Chem Biol 2000, 7:R85-R94. (Pubitemid 30199611)
3. Fletcher S, Hamilton AD: Protein surface recognition and proteomimetics: mimics of protein surface structure and function. Curr Opin Chem Biol 2005, 9: 632-638. (Pubitemid 41612192)
4. Wilson AJ: Inhibition of protein-protein interactions using designed molecules. Chem Soc Rev 2009, 38: 3289-3300.
5. Buerger C, Groner B: Bifunctional recombinant proteins in cancer therapy: cell penetrating peptide aptamers as inhibitors of growth factor signaling. J Cancer Res Clin Oncol 2003, 129: 669-675. (Pubitemid 38002297)
6. Seidah NG: Proprotein Convertase Subtilisin Kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologies. Curr Pharm Des 2013, 19: 3161-3172.
7. Traczewski P, Rudnicka L: Treatment of systemic lupus erythematosus with epratuzumab. Br J Clin Pharmacol 2011, 71: 175-182.
8. Nord K, Gunneriusson E, Ringdahl J, Stahl S, Uhlen M, Nygren PA: Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nat Biotechnol 1997, 15: 772-777. (Pubitemid 27329481)
9. Winter A, Higueruelo AP, Marsh M, Sigurdardottir A, Pitt WR, Blundell TL: Biophysical and computational fragment-based approaches to targeting protein-protein interactions: applications in structure-guided drug discovery. Q Rev Biophys 2012, 45: 383-426.
10. Erlanson DA, Braisted AC, Raphael DR, Randal M, Stroud RM, Gordon EM, Wells JA: Site-directed ligand discovery. Proc Natl Acad Sci U S A 2000, 97: 9367-9372. (Pubitemid 30650781)
11. Arkin MR, Randal M, DeLano WL, Hyde J, Luong TN, Oslob JD, Raphael DR, Taylor L, Wang J, McDowell RS et al.: Binding of small molecules to an adaptive protein-protein interface. Proc Natl Acad Sci U S A 2003, 100: 1603-1608. (Pubitemid 36254494)
12. Hopkins A, Groom C, Alex A: Ligand efficiency: a useful metric for lead selection. Drug Discov Today 2004, 9: 430-431. (Pubitemid 38510559)
13. Shuker S, Hajduk P, Meadows R, Fesik S: Discovering high-affinity ligands for proteins: SAR by NMR. Science 1996, 274: 1531-1534. (Pubitemid 26403929)
14. Blundell TL, Jhoti H, Abell C: High-throughput crystallography for lead discovery in drug design. Nat Rev Drug Discov 2002, 1: 45-54. (Pubitemid 37361403)
15. Hajduk PJ, Greer J: A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov 2007, 6: 211-219. (Pubitemid 46344625)
16. Murray CW, Blundell TL: Structural biology in fragment-based drug design. Curr Opin Struct Biol 2010, 20: 497-507.
17. Meireles LM, Domling AS, Camacho CJ: ANCHOR: a web server and database for analysis of protein-protein interaction binding pockets for drug discovery. Nucleic Acids Res 2010, 38:W407-W411.
18. Blundell TL, Sibanda BL, Montalvao RW, Brewerton S, Chelliah V, Worth CL, Harmer NJ, Davies O, Burke D: Structural biology and bioinformatics in drug design: opportunities and challenges for target identification and lead discovery. Philos Trans R Soc Lond B: Biol Sci 2006, 361: 413-423. (Pubitemid 44870098)
19. Scott DE, Ehebauer MT, Pukala T, Marsh M, Blundell TL, Venkitaraman AR, Abell C, Hyvonen M: Using a fragment-based approach to target protein-protein interactions. Chembiochem 2013, 14: 332-342.
20. Navratilova I, Hopkins AL: Emerging role of surface plasmon resonance in fragment-based drug discovery. Future Med Chem 2011, 3: 1809-1820.
21. Valkov E, Sharpe T, Marsh M, Greive S, Hyvönen M: Targeting protein-protein interactions and fragment-based drug discovery. Top Curr Chem 2012, 317: 145-179.
22. Coyne AG, Scott DE, Abell C: Drugging challenging targets using fragment-based approaches. Curr Opin Chem Biol 2010, 14: 299-307.
23. Firth NC, Brown N, Blagg J: Plane of best fit: a novel method to characterize the three-dimensionality of molecules. J Chem Inf Model 2012, 52: 2516-2525.
24. Craik DJ, Fairlie DP, Liras S, Price D: The future of peptide-based drugs. Chem Biol Drug Des 2013, 81: 136-147.
25. Azzarito V, Long K, Murphy NS, Wilson AJ: Inhibition of alpha-helix-mediated protein-protein interactions using designed molecules. Nat Chem 2013, 5: 161-173.
26. Wysoczanski P, Mart RJ, Loveridge EJ, Williams C, Whittaker SB, Crump MP, Allemann RK: NMR solution structure of a photoswitchable apoptosis activating Bak peptide bound to Bcl-xL. J Am Chem Soc 2012, 134: 7644-7647.
27. Whitby LR, Boger DL: Comprehensive peptidomimetic libraries targeting protein-protein interactions. Acc Chem Res 2012, 45: 1698-1709.
28. Ko E, Raghuraman A, Perez LM, Ioerger TR, Burgess K: Exploring key orientations at protein-protein interfaces with small molecule probes. J Am Chem Soc 2013, 135: 167-173.
29. Braun CR, Mintseris J, Gavathiotis E, Bird GH, Gygi SP, Walensky LD: Photoreactive stapled BH3 peptides to dissect the BCL-2 family interactome. Chem Biol 2010, 17: 1325-1333.
30. Grigoryev Y: Stapled peptide to enter human testing, but affinity questions remain. Nat Med 2013, 19:120.
31. Edwards TA, Wilson AJ: Helix-mediated protein-protein interactions as targets for intervention using foldamers. Amino Acids 2011, 41: 743-754.
32. Verdine G, Walensky L: The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. Clin Cancer Res 2007, 13: 7264-7270.
33. Blackwell HE, Grubbs RH: Highly efficient synthesis of covalently cross-linked peptide helices by ring-closing metathesis. Angew Chem Int Ed 1998, 37: 3281-3284. (Pubitemid 29016745)
34. Schafmeister CE, Po J, Verdine GL: An all-hydrocarbon cross-linking system for enhancing the helicity and metabolic stability of peptides. J Am Chem Soc 2000, 122: 5891-5892. (Pubitemid 30432299)
35. Walensky LD, Kung AL, Escher I, Malia TJ, Barbuto S, Wright RD, Wagner G, Verdine GL, Korsmeyer SJ: Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 2004, 305: 1466-1470. (Pubitemid 39167667)
36. Gavathiotis E, Suzuki M, Davis ML, Pitter K, Bird GH, Katz SG, Tu H-C, Kim H, Cheng EHY, Tjandra N et al.: BAX activation is initiated at a novel interaction site. Nature 2008, 455: 1076-1081.
37. Gavathiotis E, Reyna DE, Bellairs JA, Leshchiner ES, Walensky LD: Direct and selective small-molecule activation of proapoptotic BAX. Nat Chem Biol 2012, 8: 639-645.
38. Baek S, Kutchukian PS, Verdine GL, Huber R, Holak TA, Lee KW, Popowicz GM: Structure of the stapled p53 peptide bound to Mdm2. J Am Chem Soc 2012, 134: 103-106.
39. Bernal F, Wade M, Godes M, Davis TN, Whitehead DG, Kung AL, Wahl GM, Walensky LD: A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer Cell 2010, 18: 411-422.
40. Bernal F, Tyler AF, Korsmeyer SJ, Walensky LD, Verdine GL: Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide. J Am Chem Soc 2007, 129: 2456-2457. (Pubitemid 46364050)
41. Bird GH, Madani N, Perry AF, Princiotto AM, Supko JG, He X, Gavathiotis E, Sodroski JG, Walensky LD: Hydrocarbon double- stapling remedies the proteolytic instability of a lengthy peptide therapeutic. Proc Natl Acad Sci U S A 2010, 107: 14093-14098.
42. Moellering RE, Cornejo M, Davis TN, Del Bianco C, Aster JC, Blacklow SC, Kung AL, Gilliland DG, Verdine GL, Bradner JE: Direct inhibition of the NOTCH transcription factor complex. Nature 2009, 462: 182-188.
43. Stewart ML, Fire E, Keating AE, Walensky LD: The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer. Nat Chem Biol 2010, 6: 595-601.
44. Grossmann TN, Yeh JT-H, Bowman BR, Chu Q, Moellering RE, Verdine GL: Inhibition of oncogenic Wnt signaling through direct targeting of b-catenin. Proc Natl Acad Sci U S A 2012, 109: 17942-17947.
45. Zhang H, Curreli F, Zhang X, Bhattacharya S, Waheed AA, Cooper A, Cowburn D, Freed EO, Debnath AK: Antiviral activity of alpha-helical stapled peptides designed from the HIV-1 capsid dimerization domain. Retrovirology 2011, 8:28.
46. Phillips C, Roberts LR, Schade M, Bazin R, Bent A, Davies NL, Moore R, Pannifer AD, Pickford AR, Prior SH et al.: Design and structure of stapled peptides binding to estrogen receptors. J Am Chem Soc 2011, 133: 9696-9699.
47. Sviridov DO, Ikpot IZ, Stonik J, Drake SK, Amar M, Osei-Hwedieh DO, Piszczek G, Turner S, Remaley AT: Helix stabilization of amphipathic peptides by hydrocarbon stapling increases cholesterol efflux by the ABCA1 transporter. Biochem Biophys Res Commun 2011, 410: 446-451.
48. Cui HK, Zhao B, Li Y, Guo Y, Hu H, Liu L, Chen YG: Design of stapled alpha-helical peptides to specifically activate Wnt/beta-catenin signaling. Cell Res 2013, 23: 581-584.
49. Cui H-K, Qing J, Guo Y, Wang Y-J, Cui L-J, He T-H, Zhang L, Liu L: Stapled peptide-based membrane fusion inhibitors of hepatitis C virus. Bioorg Med Chem 2013, 21: 3547-3554.
50. Brown CJ, Quah ST, Jong J, Goh AM, Chiam PC, Khoo KH, Choong ML, Lee MA, Yurlova L, Zolghadr K et al.: Stapled peptides with improved potency and specificity that activate p53. ACS Chem Biol 2013, 8: 506-512.
51. Joseph TL, Lane DP, Verma CS: Stapled BH3 peptides against MCL-1: mechanism and design using atomistic simulations. PLoS ONE 2012, 7:e43985.
52. Okamoto T, Zobel K, Fedorova A, Quan C, Yang H, Fairbrother WJ, Huang DC, Smith BJ, Deshayes K, Czabotar PE: Stabilizing the pro-apoptotic BimBH3 helix (BimSAHB) does not necessarily enhance affinity or biological activity. ACS Chem Biol 2013, 8: 297-302.
53. Prinz F, Schlange T, Asadullah K: Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov 2011, 10:712.
54. Adamski-Werner SL, Palaninathan SK, Sacchettini JC, Kelly JW: Diflunisal analogues stabilize the native state of transthyretin. potent inhibition of amyloidogenesis. J Med Chem 2003, 47: 355-374. (Pubitemid 38057880)
55. Pommier Y, Cherfils J: Interfacial inhibition of macromolecular interactions: nature's paradigm for drug discovery. Trends Pharmacol Sci 2005, 26: 138-145. (Pubitemid 40313593)
56. Thiel P, Kaiser M, Ottmann C: Small-molecule stabilization of protein-protein interactions: an underestimated concept in drug discovery? Angew Chem Int Ed Engl 2012, 51: 2012-2018.
57. Pommier Y, Marchand C: Interfacial inhibitors: targeting macromolecular complexes. Nat Rev Drug Discov 2012, 11: 25-36.
58. Wisén S, Bertelsen EB, Thompson AD, Patury S, Ung P, Chang L, Evans CG, Walter GM, Wipf P, Carlson HA et al.: Binding of a small molecule at a protein-protein interface regulates the chaperone activity of Hsp70-Hsp40. ACS Chem Biol 2010, 5: 611-622.
59. Block P, Weskamp N, Wolf A, Klebe G: Strategies to search and design stabilizers of protein-protein interactions: a feasibility study. Proteins 2007, 68: 170-186. (Pubitemid 46871591)
60. Cai Z, Greene MI, Berezov A: Modulation of biomolecular interactions with complex-binding small molecules. Methods (San Diego, CA) 2008, 46: 39-46.
61. Lawson ADG: Antibody-enabled small-molecule drug discovery. Nat Rev Drug Discov 2012, 11: 519-525.
62. Edfeldt FNB, Folmer RHA, Breeze AL: Fragment screening to predict druggability (ligandability) and lead discovery success. Drug Discov Today 2011, 16: 284-287.
63. Tickle S, Adams R, Brown D, Griffiths M, Lightwood D, Lawson A: High-throughput screening for high affinity antibodies. J Assoc Lab Autom 2009, 14: 303-307.
64. Higueruelo AP, Schreyer A, Bickerton GRJ, Pitt WR, Groom CR, Blundell TL: Atomic interactions and profile of small molecules disrupting protein-protein interfaces: the TIMBAL database. Chem Biol Drug Des 2009, 74: 457-467.
65. Pellegrini L, Yu DS, Lo T, Anand S, Lee M, Blundell TL, Venkitaraman AR: Insights into DNA recombination from the structure of a RAD51-BRCA2 complex. Nature 2002, 420: 287-293. (Pubitemid 35398178)
66. Rose R, Erdmann S, Bovens S, Wolf A, Rose M, Hennig S, Waldmann H, Ottmann C: Identification and structure of small-molecule stabilizers of 14-3-3 protein-protein interactions. Angew Chem Int Ed Engl 2010, 49: 4129-4132.